# Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC

> **NCT02187081** · NA · UNKNOWN · sponsor: **Southwest Hospital, China** · enrollment: 380 (estimated)

## Conditions studied

- HCC

## Interventions

- **PROCEDURE:** radiofrequency ablation plus Sorafenib
- **PROCEDURE:** Radiofrequency ablation

## Key facts

- **NCT ID:** NCT02187081
- **Lead sponsor:** Southwest Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-15
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02187081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02187081, "Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT02187081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*